Format

Send to

Choose Destination
Front Pediatr. 2017 Feb 16;5:18. doi: 10.3389/fped.2017.00018. eCollection 2017.

Recent Progress of the ARegPKD Registry Study on Autosomal Recessive Polycystic Kidney Disease.

Collaborators (182)

Eid LA, Ranguelov N, Adams B, van Hoeck K, Raes A, Mekahli D, Collard L, Lombet J, Maquet J, Cachat F, Schalk G, Seeman T, Ortiz Bruechle N, Zerres K, Thumfart J, Briese S, Querfeld U, Hoppe B, Feldkoetter M, Kirschstein M, Gruening G, Beck BB, Benzing T, Buettner R, Dötsch J, Goebel H, Grundmann F, Hero B, Kurschat C, Weber LT, Mayer B, Weber J, Ritter B, Benz K, Galiano M, Tzschoppe A, Buchholz B, Buescher R, Buescher A, Latta K, Häffner K, Pohl M, Gross O, Krügel J, Stock J, Patzer L, Teichler H, Oh J, Schild R, Illig T, Klopp N, Pape L, Wahrendorf S, Bernhardt W, Doyon A, Wuehl E, Vinke T, Sander A, Kunzmann K, Bergmann C, Wygoda S, Henn M, Wiemann D, Blaschke K, Derichs U, Beetz R, Jeck N, Klaus G, Fehrenbach H, Hampel T, Zoetler S, Wallot M, Kyrieleis H, Lange-Sperandio B, Ponsel S, Kusser F, Hoefele J, Uetz B, Benz M, Schmidt S, Huppertz-Kessler C, Kranz B, Koenig J, Titieni A, Boeswald M, Staude H, Jacoby U, Wurm D, Leichter HE, Bald M, Billing H, Gessner M, Beringer O, Ilmoja ML, Soliman NA, Nabhan MM, Ariceta G, Lara LE, Garcia-Gonzalez MA, Diaz-Rodriguez C, Garcia-Vidal M, Ranchin B, Shroff R, Sterenborg R, Davitala T, Papachristou F, Stabouli S, Sallay P, Hooman N, Ardissino G, Testa S, Massella L, Emma F, Jankauskiene A, Cerkauskiene R, Azukaitis K, Bokenkamp A, van Wijk J, Taranta-Janusz K, Wasilewska A, Zagozdzon I, Balasz-Chmielewska I, Miklaszewska M, Zachwieja K, Drozdz D, Tkaczyk M, Stanczyk M, Sikora P, Zaniew M, Litwin M, Niemirska A, Wicher D, Jankowska I, Antoniewicz J, Lesiak J, Lipinski P, Szczepanska M, Adamczyk P, Morawiec-Knysak A, Caldas Afonso A, Teixeira A, Milosevski-Lomic G, Paripović D, Peco-Antic A, Prikhodina L, Papizh S, Bayazit AK, Anarat A, Melek E, Bayrakci US, Kantar A, Cayci S, Baskin UE, Duzova A, Yuzbasioglu A, Soylu A, Kavukcu S, Kalman S, Evrengül H, Yüksel S, Kara A, Gurgoze MK, Candan C, Sever L, Caliskan S, Canpolat N, Emre S, Yilmaz A, Gökce I, Alpay H, Akinci N, Mir S, Sozeri B, Dursun I, Poyrazoglu HM, Dusunsel R, Nalcacioglu H, Ekinci Z, Tabel Y, Delibas A, Övünc Hacihamdioglu D, Guay-Woodford L.

Author information

1
Department of Pediatrics, University Hospital of Cologne , Cologne , Germany.
2
Division of Pediatric Nephrology, Centre for Pediatrics and Adolescent Medicine, Heidelberg University Medical Centre , Heidelberg , Germany.
3
Department of Pediatrics, University Hospital of Cologne, Cologne, Germany; Center for Molecular Medicine, University Hospital of Cologne, Cologne, Germany; Nephrology Research Laboratory, Department II of Internal Medicine, University Hospital of Cologne, Cologne, Germany.

Abstract

Autosomal recessive polycystic kidney disease (ARPKD) is a rare monogenic disease with a severe phenotype often presenting prenatally or in early childhood. With its obligate renal and hepatic involvement, ARPKD is one of the most important indications for liver and/or kidney transplantation in childhood. Marked phenotypic variability is observed, the genetic basis of which is largely unknown. Treatment is symptomatic and largely empiric as evidence-based guidelines are lacking. Therapeutic initiatives for ARPKD face the problem of highly variable cohorts and lack of clinical or biochemical risk markers without clear-cut clinical end points. ARegPKD is an international, multicenter, retro- and prospective, observational study to deeply phenotype patients with the clinical diagnosis of ARPKD. Initiated in 2013 as a web-based registry (www.aregpkd.org), ARegPKD enrolls patients across large parts of Europe and neighboring countries. By January 2017, more than 400 patients from 17 mostly European countries have been registered in the ARPKD registry study with significant follow-up data. Due to comprehensive retro- and prospective data collection and associated biobanking, ARegPKD will generate a unique ARPKD cohort with detailed longitudinal clinical characterization providing a basis for future clinical trials as well as translational research. Hence, ARegPKD is hoped to contribute to the pathophysiological understanding of the disease and to the improvement of clinical management.

KEYWORDS:

ARPKD; PKHD1; ciliopathy; congenital hepatic fibrosis; fibrocystin; polycystic kidney disease

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center